Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

NeoTherapeutics50 enrolled

Overview

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Peripheral Nervous System Diseases Chemotherapy-Induced Peripheral Neuropathy

Interventions

leteprinim potassium (Neotrofin)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

* Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy. * Sensory or motor neuropathy must be \>/= grade 2 per Common Toxicity Criteria at baseline. * In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable. * Patient must have normal hematological cell counts. * Patient must have a life expectancy of \>/= 3 months.

Locations (6)

Alta Bates Comprehensive Cancer Center

Berkeley, California, United States

Providence St. Joseph Medical Center

Burbank, California, United States

Providence Holy Cross Medical Center

Mission Hills, California, United States

Washington University School of Medicine

St Louis, Missouri, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.